您的位置：首页 > 产品中心 > 1086062-66-9， GSK2126458
GSK2126458
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 4119084 | 10 MG | 1010 | |||
| 4119084 | 50 MG | 3550 |
产品别名
1086062-66-9
GSK2126458
GSK 2126458
GSK-458
GSK2126458A
GSK-2126458
GSK 458
2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide
GSK458
Omipalisib
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C25H17F2N5O3S |
| Molecular weight | 505.50 |
| MDL number | MFCD16038929 |
| Biochem/physiol Actions【生化/生理作用】 | GSK2126458 (GSK458) is an orally active, highly potent and selective ATP site inhibitor against phosphoinositide 3-kinase (PI3K p110α CI50 = 40 pM; p100 α/δ/γ/β Ki = 19/24/60/130 pM; p110α E542K/E545K/H1047R Ki = 8/8/9 pM), mTOR (mTORC1/C2 Ki = 180/300 pM) and DNA-PK (IC50 = 280 pM) with >10,000-fold selectivity over more than 240 other kinases evaluated. GSK458 inhibits cellular AKT pS473 and growth of breast cancer cells in cultures (pAKT/growth IC50 = 0.41/3 nM/T-47D and 0.18/2.4/BT-474) and in vivo (0.3-3 mg/kg, 5x per wk for 3 wks p.o. in mice). |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| color【颜色】 | white to beige |
| solubility【溶解性】 | DMSO: 2 mg/mL, clear |
| storage temp.【储存温度】 | 2-8℃ |
| SMILES string | FC(C=C1F)=CC=C1S(NC2=CC(C3=CC4=C(C5=CN=NC=C5)C=CN=C4C=C3)=CN=C2OC)(=O)=O |
安全信息
| Pictograms【象形图】 | GHS07,GHS08 |
| Signal word【警示用语：】 | Danger |
| Hazard Statements | H302 - H361fd - H372 |
| Precautionary Statements | P202 - P260 - P264 - P270 - P301 + P312 - P308 + P313 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral - Repr. 2 - STOT RE 1 |
| Storage Class Code【储存分类代码】 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
